Bedaquiline, Delamanid, Linezolid, and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis

2022109 citationsJournal Articlebronze Open Access

Authors

Chandrasekaran Padmapriyadarsini · National Institute of Research in Tuberculosis

Vikram Vohra · LRS Institute of Tuberculosis and Respiratory Diseases

Anuj Bhatnagar

Rajesh Solanki · B.J. Medical College

Rathinam Sridhar · Government Hospital of Thoracic Medicine

Lalitkumar Anande · Bombay Hospital

M Muthuvijaylakshmi · National Institute of Research in Tuberculosis

Abstract

After 24-36 weeks of treatment, this regimen resulted in a satisfactory favorable outcome in pulmonary MDR-TB patients with additional drug resistance. Cardiotoxicity was minimal, and myelosuppression, while common, was detected early and treated successfully.

Topics & Keywords

Tuberculosis Research and Epidemiology Pneumonia and Respiratory Infections Infectious Diseases and Tuberculosis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Infectious Diseases

Volume 76, Issue 3, pp. e938-e946

DOI: 10.1093/cid/ciac528

Field-Weighted Citation Impact: 10.32